Illumina is trading at $256.29, down 4.28%, with no clear reason for the decline established in available evidence.

  • No verified October 8 company-specific announcement or catalyst surfaced; coverage highlighted prior clinical-sales and AI optimism.
  • Elevated oil prices and bond yields weighed on markets, but supplied index moves do not establish broader weakness as the cause of Illumina’s larger drop.
  • The decline follows losses on October 6 and October 7; available evidence identifies no direct cause.